Terremoto Biosciences raised $108 million in a Series C financing to advance small-molecule drugs targeting AKT, with the company describing its covalency technology approach to improve efficacy and safety. New investors include RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines, with participation from OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management. Terremoto said it is testing its lead therapy TER-2013 in a Phase 1 program for solid tumors with specific genetic alterations, while TER-4480 is expected to enter the clinic in hereditary hemorrhagic telangiectasia (HHT), a disease with no approved therapies. The funding arrives as larger venture checks concentrate behind companies that have differentiated platform claims and clear early-clinical milestones, reflecting a continued willingness to bankroll competitive oncology and rare-disease mechanisms.